Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the ...

INCHEON, South Korea and CAMBRIDGE, MA, USA I November 18, 2024 I Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European ...

The study confirmed that Afqlir has equivalent efficacy and comparable safety to its reference medicine, Eylea.

Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The ...

(RTTNews) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) Monday announced that the European Commission (EC) has approved Opuviz, a biosimilar to Regeneron Pharmaceuticals' Aflibercept.

The NHS is warning people to be vigilant for a potentially fatal symptom that could indicate heart failure. The health body ...

There is no cure for heart failure and it typically gets worse over time with around half of patients dying within five years ...

On Thursday, the EMA (European Medicines Agency) approved the long-awaited treatment after initially blocking it in July, ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

The NHS has issued a warning to be vigilant over an uncomfortable symptom in the legs that could indicate a potentially ...